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Background: There is lack of large data from South-Asian region on atrial fibrillation and it is imperative that
clinical presentation, prognostic factors, management pursued, and outcomes are known for this part of the
world. Once collective evidence for the region is known, region-specific guidelines can be laid forward.
Objectives: To evaluate clinical characteristics and prognostic factors of atrial fibrillation at a tertiary care center
of Pakistan.
Methods: This was a retrospective study conducted at a tertiary care center of Pakistan. Period of study ranged
from July–December 2018. All hospitalized patients who were admitted with atrial fibrillation as a primary or
associated diagnosis were enrolled.
Results: A total of 636 patients were enrolled. The mean age was 68.5 ± 12 years and 49.5% (315) were male.
90.6% of the patients were admitted via emergency room. Majority (59.9%) had previously known AF and 40%
developed new-onset AF during the hospital stay. Hypertension was the most common co-morbid condition
(85.4%) followed by Diabetes Mellitus (40.1%). At least 9% had rheumatic heart disease. The median
CHA2DS2VASc and HASBLED scores were 4 and 2 respectively. More than one-third of patients had sepsis as a
primary diagnosis (36.8%). The in-hospital mortality of patients with atrial fibrillation was 6.7%. Patients with
new-onset AF had higher mortality. Sepsis and stroke were independently associated with a higher mortality.
There was no significant difference in median CHA2DS2VASc and HASBLED scores for patients with new-onset
and previously known AF. On discharge, 83% of the eligible patients received oral anticoagulation.
Conclusion: There was higher prevalence of chronic co-morbid conditions in the studied population leading to a
higher CHA2DS2VASC Score. Sepsis and stroke were independently associated with higher in-hospital mortality.

1. Introduction
Atrial fibrillation (AF) is a supraventricular tachyarrhythmia due to
an uncoordinated atrial electrical activation resulting in ineffective
atrial contraction [1]. It has a complex pathophysiology. Various
mechanisms have been postulated and the most widely accepted one
suggests an inter-play of initiating drivers or triggers and an abnormal
structural substrate (atria and pulmonary veins). Presence of structural
loop (for example a diseased left atrium tissue) allows the arrhythmia to

sustain by allowing multiple re-entry circuits to perpetuate [2]. AF is
characterized on a surface electrocardiogram (ECG) by absence of
identifiable P wave and irregular ventricular rate due to variable
atrioventricular (AV) conduction [3].
AF is the most frequent sustained arrhythmia identified in clinical
practice [4]. Patients with atrial fibrillation usually present with palpi
tations, dyspnea, and fatigue and/or chest pain. The presentation can be
subclinical or asymptomatic. It is associated with a higher risk of cere
brovascular accidents (most commonly), heart failure and recurrent
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hospitalization. [5,6]; Atrial fibrillation can present as a primary disease
or more often co-exist in patients with multiple comorbidities, such as
hypertension, diabetes mellitus, coronary artery disease, cardiomyopa
thies, valvular heart diseases, obesity, alcohol, thyroid diseases, and
chronic lung diseases [7]. Age is one of the major risk factors for
developing atrial fibrillation, as much as, according to an estimate the
lifetime risk of developing atrial fibrillation is 1/3rd [1]. The lifetime
chance of developing atrial fibrillation increases after fifth decade [8].
With increase in life expectancy, more people now live with chronic
co-morbid conditions. Hence, the prevalence of AF is estimated to rise by
at least 2.5-fold by 2050 [4]. Although globally present, variation in

disease burden and clinical presentation with respect to race, ethnicity
and geography would not be surprising [9,10] given the difference in
prevalence of co-morbid conditions across different regions of the world.
In an observational study, more than 6% of the acute hospital admis
sions in Pakistan were due to atrial fibrillation [11]. Another study
identified an incidence of 26% in patients undergoing coronary artery
bypass grafting (CABG) [12].
Clinical research providing framework for guidelines over the last 2
decades are largely based on data from regions other than South-Asia
[13–15]. There is lack of large data from South-Asian region and it is
imperative that clinical presentation, prognostic factors, management

Fig. 1. Flow Diagram representing patient recruitment.
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pursued, and outcomes are known for this part of the world. Once col
lective evidence for the region is known, region-specific guidelines can
be laid forward.

Of 636 patients, 381 (59.9%) patients had previously diagnosed
persistent or paroxysmal atrial fibrillation and 255 (40.1%) developed
new onset atrial fibrillation during the hospital stay. Baseline charac
teristics of both the groups (new-onset and previously diagnosed atrial
fibrillation) were as shown in Table 1. Majority of the patients (90.6%)
got admitted through emergency department and sepsis/infection was
the reason for hospitalization in 234 (36.8%) patients followed by heart
failure in 75 (11.8%), acute coronary syndrome in 54 (8.5%) and
chronic lung disease in 51 (8.0%). Only 60 (9.4%) patients were
admitted electively via outpatient clinics.
Treatment: Out of 636 patients, 489 (76.9%) patients had well
controlled ventricular rate (<110beats/min) and rest of them (147) had
uncontrolled ventricular rate. During the hospital stay, beta blockers
were given in 465 (73.1%) patients, (relative contraindication to beta
blockers was present in 162 (25.5%) patients), non-dihydropyridine
calcium channel blockers in 63 (9.9%) patients. None of the patients
received digoxin and none required emergency electrical cardioversion.
Median CHA2DS2VASc score in our study population was 4 with an
interquartile range (IQR) of 7and median HASBLED score was 2 with an
IQR of 4. Out of 321 female patients, 303 (94.4%) had a CHA2DS2VASc
score of ≥2 and oral anticoagulation was prescribed to 222 (73.2%) on
discharge. Among male participants, 306 (97.1%) had a CHA2DS2VASc
score of ≥1 and 207 (68%) of them received anticoagulation.
Intravenous amiodarone was given in 255 (40.1%) patients, 246 of
them were those with new onset AF. Mean ventricular rate of these
patients was 152 ± 17 bpm and mean systolic blood pressure was 103 ±
6.4 mmHg at the time when amiodarone was started. Around 82% of the
patients received intravenous amiodarone bolus (150 mg) before

2. Methodology
Study Population: It was a retrospective observational study con
ducted at a tertiary care teaching hospital of the country. The study was
approved by the ethical review committee of the hospital (ERC No. 0191008-2905). Both male and females, age ≥18, who were found to have
atrial fibrillation as a primary or associated diagnosis were included.
Diagnosis of AF was confirmed on a 12-lead ECG. Hospital record for
651 patients meeting the inclusion criteria was retrieved from the
electronic medical record system for a study period from July 1, 2018 to
December 31, 2018. Fifteen patients were excluded who did not have
electrocardiographic evidence of atrial fibrillation (Fig. 1).
For all the patients, basic demographic information, reason of
admission, co-morbid conditions, and duration of arrhythmia were
noted. Recorded comorbidities included DM, hypertension, coronary
artery disease, heart failure, cardiomyopathy, valvular heart disease,
chronic obstructive pulmonary disease, and hyperthyroidism. Echocar
diographic data was reviewed for left atrial (LA) dimension, LA volume
index and left ventricular (LV) systolic function.
Patients were labeled as diabetic if they had HbA1c > 6.5 gm/dl or
were already on treatment for DM. Hypertension was defined as an
average of two readings of systolic blood pressure ≥140 mmHg, a dia
stolic blood pressure ≥90 mmHg or if patient was already taking anti
hypertensive medications. Coronary artery disease was defined as ≥50%
stenosis in at least one of the epicardial coronary arteries. Cardiomy
opathy was defined as LV ejection fraction of ≤50%. Chronic obstructive
pulmonary disease was defined as a forced expiratory volume in 1st
second to forced vital capacity ratio of <70% of the predicted value.
Patients were labeled hyperthyroid if they had low serum TSH and high
serum concentration of free T4 or T3 as per the laboratory reference
range.
In hospital Monitoring: All patients were followed from the time of
inclusion to the time of discharge or till inpatient death. Hemodynamic
parameters including heart rate and blood pressure were recorded at the
time of inclusion for patients with known atrial fibrillation and at the
time of onset of arrhythmia for those with new onset atrial fibrillation.
Patients’ treatment records were retrieved. Complications related to
atrial fibrillation, or its treatment were also recorded.
Statistical Analysis: After creating a database, the data was enco
ded. All statistical analyses were performed using the Statistical Package
for Social Sciences (SPSS) version 23. Continuous variables were
expressed as mean value ± standard deviation and categorical variables
were expressed as frequencies and percentage. Multivariate logistic
regression was done to analyze the risk factors and predictors of inhospital mortality and p value of <0.05 was considered significant.
Ethical approval was obtained from the ethical review committee of
the hospital. The work has been reported in line with the STROCSS
criteria [16]. This study has been registered with clinicaltrial.gov (UIN
number: NCT05082558).

Table 1
Baseline Characteristics of patients hospitalized with atrial fibrillation.

Mean Age

Total Cohort
N = 636

Paroxysmal/
Persistent AF
N = 381

New –onset
AF
N = 255

68.5 ± 12
Years
195 (30.7%)
237 (37.3%)

67.6 ± 12 Years
135 (35.4%)
132 (34.6%)

69.9 ± 10
Years
60 (23.5%)
105 (41.2%)

114 (30.0%)

90 (35.3%)

168 (44.1%)
213 (55.9%)

147 (57.6%)
108 (42.4%)

327 (85.8%)
223 (58.5%)
33 (8.7%)

216 (84.7%)
149 (58.4%)
33 (12.9%)

117 (30.7%)
99 (26%)
57 (15%)
30 (7.8%)

84 (32.9%)
18 (7.1%)
0 (0%)
9 (3.6%)

4 (IQR 7)
2 (IQR 4)

4 (IQR 6)
2 (IQR 4)

48.1 ± 11%
57 (15%)

49.4 ± 10%
15 (6%)

45 ± 17 ml/m2
108 (28.3%)

29.5±8 ml/
m2
03 (1.2%)

33 (8.6%)

0 (0%)

120 (31.5%)

39 (15.3%)

15 (3.9%)

03 (1.2%)

150 (39.4%)

60 (23.5%)

Patients with age <65 years
Patients with age 65–74
years
Patients with age ≥75 years
204 (32.1%)
Gender
Male
315 (49.5%)
Female
321 (50.5%)
Co-morbid Conditions
HTN
543 (85.4%)
DM
372 (58.5%)
CKD
66 (10.4%)
Chronic Lung Disease
51 (8.0%)
CAD
201 (31.6%)
CVA
117 (18.4%)
Rheumatic Heart Disease
57 (9.0%)
Thyroid Disorders
39 (6.1%)
Stroke and Bleeding Risk
CHA2DS2VASc (Median)
4 (IQR 7)
HASBLED (Median)
2 (IQR 4)
Echocardiographic Parameters
Mean Ejection Fraction
48.6 ± 11%
Patients with severe LV
72 (11.3%)
dysfunction
Mean Left Atrial Volume
38.8 ± 16
Index
ml/m2
Patients with Severe LA
111 (17.4%)
enlargement
Moderate or more than
33 (5.2%)
moderate MS
Moderate or more than
159 (25%)
moderate MR
Moderate or more than
18 (2.8%)
moderate AS
Moderate or more than
210 (33%)
moderate TR

3. Results
Baseline characteristics: From July–December 2018, a total of
36,925 patients were admitted to the hospital. Atrial fibrillation was
present in 1.72% (636) of the patients (Fig. 1). Out of 636 patients who
met the inclusion criteria, 315 (49.5%) were male with a mean age of
68.5 ± 12 years. Majority (69%) were of age ≥65 years.
Diabetes mellitus was found in 372 (58.5%) patients, hypertension in
543 (85.4%) patients, coronary artery disease in 201 (31.6%) patients
and chronic kidney disease was found in 66 (10.4%) patients. A total of
117 (18.4%) had prior CVA, 39 (6.1%) patients had thyroid disorder and
57 (9%) had prior rheumatic heart disease.
3
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starting on infusion at 1 mg/min for 6 h followed by 0.5 mg/min for next
18 h. Out of 246 patients with new onset AF who received intravenous
amiodarone, 60 (24.3%) reverted to sinus rhythm within 6 h of infusion
and 182 (74%) were found in sinus rhythm at the end of 24 h of infusion.
After intravenous infusion, oral amiodarone was continued in 142
(58.9%) of the patients during the hospital stay.
Of all the study population, 429 (67.5%) patients got oral anti
coagulation on discharge and 93 (14.6%) patients did not get anti
coagulation due to contraindications. Contraindications included
hematuria, gastrointestinal bleed, coagulopathy, and previous intra
cranial hemorrhage. Novel oral anticoagulants were prescribed to 336
(52.8%) patients and 93 (14.6%) patients received vitamin K antagonist
on discharge. More women received anticoagulation on discharge as
compared to men (Table .2).
Complications: Hematuria was the most common complication
observed in a total of 32 (6.6%) patients during the hospital stay,
requiring transient discontinuation of anticoagulation. 5 (1.04%) of the
patients developed gastrointestinal bleed requiring blood transfusion.
None of the patients developed intracranial or retroperitoneal bleeding.
No significant drug related side effects were found in our study popu
lation and none of the participants developed CVA during the hospital
stay (Table .3).
During a mean hospital stay of 6.27 ± 5.22, 43 (6.7%) patients had
in-hospital death and sepsis/septic shock was the major cause of inhospital mortality. Sepsis was more common in patients with newonset AF, resulting in higher in-hospital mortality in the group as
compared to those with previously known AF.
Predictors of In-hospital Mortality: On multivariate logistic
regression analysis, sepsis and previous cerebrovascular accident were
found to be independently associated with in-hospital mortality, with
odds ratio of 3.953 (95% CI 1.993–7.880) and 2.225 (95% CI
1.022–4.841) respectively. There was no association between inhospital mortality and other co-morbid conditions such as hyperten
sion, coronary artery disease, chronic kidney disease, gender, and thy
roid disorders (Table 4).

Table 3
Management and complications of patients with atrial fibrillation. (n = 636).

Anti-arrhythmic therapy
Beta blockers
Non-dihydropyridine
calcium channel blockers
Intravenous amiodarone

Total
Cohort
N = 636

Patients with
Paroxysmal/
Persistent AF
N = 381

Population with
New –onset AF
N = 255

465
(73.1%)
63
(9.9%)
255
(40.1%)

315 (82.7%)

150 (58.8%)

27 (7%)

36 (14%)

9 (2.4%)

246 (96.4%)

In-hospital anticoagulation
No. of patients received
480
285 (74.8%)
anticoagulation
(75.5%)
No. of patients having
135
84 (22%)
contraindication to
(21.2%)
anticoagulation
Oral anticoagulants on discharge
Patients received novel oral
336
219 (57.5%)
anticoagulants
(52.8%)
Patients received Vitamin K
93
84 (22%)
antagonist
(14.6%)
Patients having
93
51 (13.4%)
contraindication to
(14.6%)
anticoagulants
Complications
Significant In-hospital GI
05
3 (0.79%)
bleed
(1.04%)
In-Hospital hematuria
32
25 (6.5%)
(6.6%)
In-Hospital death
43
15 (3.9%)
(6.7%)
Major cause of In-hospital death (Total deaths 51)
Sepsis/Septic shock
38
13 (3.4)
(74.5%)

195 (76.5%)
51 (20%)

117 (46%)
9 (3.5%)
42 (16.5%)

2 (0.78%)
11 (4.3%)
28 (11%)
25 (9.8)

Table 4
Predictors of In-hospital mortality of patients with atrial fibrillation.

4. Discussion

Variable

Odds
Ratio

95% Confidence
Interval

p
Value

Major trials on drug-therapy for AF have been conducted in countries
or regions other than South-Asia. Additionally, the complication spec
trum of AF and AF-related drug therapy remain largely unknown for this
part of the world. This brought us to the need of studying AF at our
center. Our study highlights the clinical characteristics, drug prescrip
tion practice for AF patients and reveals AF-related complications.
The in-hospital prevalence of AF in our study population was 1.72%
which is relatively lower than the one reported in a study from Denmark
that looked at hospital admissions data from 1997 to 2009 and reported
a prevalence of 6.8% in hospitalized patients [17]. Similarly, a study
from Kuwait over a 5-month period showed 4.24% of acute hospital
admissions were associated with AF [18]. Of note, the overall AF
prevalence is lower despite a high prevalence of risk factors for AF such
as hypertension and diabetes mellitus. On the other hand, prevalence of
new-onset AF was higher (40%) than what had been previously reported
in the literature. Allen J Walkey et al. reported that 6.64% of patients

Diabetes Mellitus
Hypertension
Coronary Artery Disease
Chronic Kidney Disease
Gender
Sepsis
Previous cerebrovascular
accidents
Left Ventricular Ejection
fraction
LA size (volume index)

0.457
0.606
1.638
1.526
1.541
3.963
2.225

0.227–0.921
0.266–1.379
0.778–3.450
0.580–4.016
0.761–3.117
1.993–7.880
1.022–4.841

0.098
0.232
0.194
0.392
0.229
0.000
0.044

0.427

0.213–0.854

0.036

1.432

0.716–2.864

0.394

developed new onset atrial fibrillation during hospitalization [19]. Haq
et al. reported AF in at least 27% of patients [11]. Possible explanation
includes a sizeable number of our patients with infection and sepsis
(30.6%), which is one of the major predisposing factors for new onset
atrial fibrillation [20]. In a prospective study conducted in Pakistan over
span of two months, 6.5% of hospitalized patients had atrial fibrillation
in background of higher incidence of rheumatic heart disease [11]. On
the other hand, we had a relatively lower prevalence of rheumatic heart
disease. This could be due to the differences in urbanicity of the two
cities.
Our study showed that patients with new onset AF did not differ from
patients with previously known AF in terms of baseline characteristics
and co-morbid conditions such as DM and hypertension. It is quite
possible that patients with new onset AF previously had asymptomatic
or paroxysmal AF which went undocumented due to the lack of hospital
encounter.
In our study population, 83% of the eligible patients (CHA2DS2VASc

Table 2
Comparison of Males and Females with atrial fibrillation.
Variables

Males

Females

P
value

Mean age (years)
Eligible for anticoagulation based on CHA2DS2VASc
(≥1 in male, ≥2 for females)
Median HASBLED
Patients having contraindications to anticoagulation
Patients received anticoagulation on discharge
Mean LA volume index (ml/m2)

69.01
306

68.05
303

0.315
0.430

2
45
207
37.99

2
48
222
39.6

0.448
0.781
0.033
0.201

4
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≥1 in males and ≥2 in females) received anticoagulation on discharge.
Haq et al. reported that only 48% of the study population was dis
charged on oral anticoagulation [11]. Moreover, in GRASP-AF registry,
more than one third of the patients in United Kingdom, who were
eligible for anticoagulation and had risk of stroke did not receive anti
coagulation [20]. This higher rate of anticoagulation prescription could
be because all the patients with AF were reviewed by cardiologist- or an
internist-on call and CHA2DS2VASc risk score was calculated for each
patient. NOACs (novel oral anticoagulants) were the most used antico
agulant in 336 (78%) of patients.
Our study population had a higher CHA2DS2VASc score with a me
dian score of 4 (No difference was observed between new onset and
previously known AF patients). Tischer et al. from Germany reported a
mean CHA2DS2VASc of 3.04 ± 1.42 in 150,408 AF patients admitted to a
tertiary care hospital [21]. With the mean age being comparable be
tween the two studies (68 ± 12 year and 67.6 ± 13.6 year), the higher
CHA2DS2VASc score can be explained by the higher prevalence of
co-morbid conditions such as hypertension (85%), DM (58.5%) and
prior CVA (18.4%). The relatively higher prevalence of prior stroke in
the study population points towards late diagnosis once complication of
AF had already happened. Considering higher prevalence of risk factors
associated with AF in the region, it is imperative that an effort for early
recognition of AF is made at a community level.
Our study highlighted a higher conversion-to-sinus rate (74%) with
use of amiodarone along with a relatively lower rate of recurrence
during the same hospital stay (7.4%). In a study by Mitric et al., 95% of
the patients with new onset AF cardioverted to sinus rhythm with
amiodarone, however AF recurred in 51.4% patients [22]. In a study by
Dursun et. Al., 81 out of 106 patients converted to normal sinus rhythm
within 24 h [23]. In another study by Kanji S. et al., 73% of the patients
with new onset atrial fibrillation, cardioverted to sinus rhythm within
24 h and around 18% developed recurrence [24]. We can conclude from
our study that use of amiodarone had better efficacy in the studied
population.
In our study population, moderate to severe mitral stenosis was seen
only in 5.2% of patients and only 9% has a diagnosis of rheumatic heart
disease (RHD). These findings are quite different from the Haq et al.
study which showed 27% of patient with rheumatic heart disease [11].
This may well represent the changing paradigm in the incidence of RHD
in urban Pakistani population in the last 10 years. We have also found
that 57% (263) patients had left atrial enlargement and 111 (17.5%) had
severe left atrial enlargement. Mean LA volume index was >38ml/m2 in
our study population, which is relatively high. This is in correlation with
age of our study population and presence of multiple comorbidities.
In our study population, majority of patients with new onset atrial
fibrillation had underlying sepsis. The in-hospital mortality was more
than 6% in our population which is higher than the comparative studies.
In a population-based study from Korea, patients with AF had four times
higher mortality as compared to general population and cerebrovascular
accident (CVA) was the most common cause of death in patients with AF
[25]. In a systemic review by Sumeet Gandhi, sepsis with new onset
atrial fibrillation was associated with increased hospital stay and
increased in-hospital mortality [26]. This is consistent with our data as
we have also identified that CVA and sepsis were independently asso
ciated with in-hospital mortality.
To our knowledge, this is one of the largest hospital-based study on
AF from Pakistan. This study identifies important information regarding
the clinical characteristics and management of AF patients in Pakistan.

6. Conclusion
The studied population had a higher CHA2DS2VASc score and mul
tiple comorbid conditions. Non-valvular atrial fibrillation was much
more common than the valvular atrial fibrillation. Sepsis and prior ce
rebrovascular accidents were independently associated with in-hospital
mortality in our study population. One-fifth of hospitalized patients with
AF had history of CVA. However, the anticoagulation rate on discharge
among eligible patient was around 83%. There is a need to recognize
patients at risk of developing atrial fibrillation and its associated com
plications. A population-based study is required to confirm above find
ings. This shall lead to the foundation of local guidelines for the
management of AF.
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